The DOI matches its Crossref record; 179 of the 179 references it cites were found in a registry or an index.
Clinical Relevance of the Pharmacokinetic Interactions of Azole Antifungal Drugs with Other Coadministered Agents
Open accessAbstract
There are currently a number of licensed azole antifungal drugs; however; only 4 (namely, fluconazole, itraconazole, posaconazole, and voriconazole) are used frequently in a clinical setting for prophylaxis or treatment of systemic fungal infections. In this article, we review the pharmacokinetic interactions of these azole antifungal drugs with other coadministered agents. We describe these (2-way) interactions and the extent to which metabolic pathways and/or other supposed mechanisms are involved in these interactions. This article provides an overview of all published drug-drug interactions in humans (either healthy volunteers or patients), and on the basis of these findings, we have developed recommendations for managing the specific interactions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Voriconazole: A New Triazole Antifungal Agent
Johnson, L. B., & Kauffman, C. A. (2003) · Clinical Infectious Diseases · doi:10.1086/367933 · Cited by 785
Center for Drug Evaluation and Research
National Cancer Institute (2020) · Definitions · doi:10.32388/doq9wu · Cited by 674
Grant, S. M., & Clissold, S. P. (1990) · Drugs · doi:10.2165/00003495-199039060-00006 · Cited by 661
Clinical Pharmacokinetics of Atorvastatin
Lennern??s, H. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342130-00005 · Cited by 623
Effects of the Antifungal Agents on Oxidative Drug Metabolism: Clinical Relevance
Venkatakrishnan, K., von Moltke, L. L., & Greenblatt, D. J. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200038020-00002 · Cited by 508
Pharmacokinetic/Pharmacodynamic Profile of Voriconazole
Theuretzbacher, U., Ihle, F., & Derendorf, H. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645070-00002 · Cited by 475
Pharmacokinetic/Pharmacodynamic Profile of Posaconazole
Li, Y., Theuretzbacher, U., Clancy, C. J., Nguyen, M. H., & Derendorf, H. (2010) · Clinical Pharmacokinetics · doi:10.2165/11319340-000000000-00000 · Cited by 450
Pharmacokinetics and Safety of Voriconazole following Intravenous- to Oral-Dose Escalation Regimens
Purkins, L., Wood, N., Ghahramani, P., Greenhalgh, K., Allen, M. J., & Kleinermans, D. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.8.2546-2553.2002 · Cited by 415
Olkkola, K. T., Backman, J. T., & Neuvonen, P. J. (1994) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1994.60 · Cited by 409
Neuvonen, P. J., Kantola, T., & Kivistö, K. T. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90165-5 · Cited by 406
Voriconazole therapeutic drug monitoring
Smith, J., Safdar, N., Knasinski, V., Simmons, W., Bhavnani, S. M., Ambrose, P. G., & Andes, D. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.4.1570-1572.2006 · Cited by 399
Identification of the Cytochrome P450 Enzymes Involved in the N-Oxidation of Voriconazole
Hyland, R., Jones, B. C., & Smith, D. A. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.5.540 · Cited by 383
Humphrey, M. J., Jevons, S., & Tarbit, M. H. (1985) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.28.5.648 · Cited by 365
Eagling, V. A., Tjia, J. F., & Back, D. J. (1998) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1998.00679.x · Cited by 333
Comparisons of catalytic selectivity of cytochrome P450 subfamily enzymes from different species
Guengerich, F. P. (1997) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(97)00068-9 · Cited by 330
Courtney, R., Wexler, D., Radwanski, E., Lim, J., & Laughlin, M. (2004) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01977.x · Cited by 327
Hariprasad, S. M. (2004) · Archives of Ophthalmology · doi:10.1001/archopht.122.1.42 · Cited by 312
Effect of itraconazole on the pharmacokinetics of atorvastatin*
Kantola, T., Kivistö, K. T., & Neuvonen, P. J. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90023-6 · Cited by 300
Courtney, R., Pai, S., Laughlin, M., Lim, J., & Batra, V. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.9.2788-2795.2003 · Cited by 299
Niemi, M., Backman, J. T., Neuvonen, M., & Neuvonen, P. J. (2003) · Diabetologia · doi:10.1007/s00125-003-1034-7 · Cited by 284
De Beule, K., & Van Gestel, J. (2001) · Drugs · doi:10.2165/00003495-200161001-00003 · Cited by 283
Varhe, A., Olkkola, K. T., & Neuvonen, P. J. (1994) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1994.184 · Cited by 278
Backman, J. T., Kivistö, K. T., Olkkola, K. T., & Neuvonen, P. J. (1998) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050420 · Cited by 266
Lutsar, I., Roffey, S., & Troke, P. (2003) · Clinical Infectious Diseases · doi:10.1086/377131 · Cited by 262
Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid
Neuvonen, P. J., & Jalava, K.-M. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90167-8 · Cited by 238
Interaction of Common Azole Antifungals with P Glycoprotein
Wang, E.-J., Lew, K., Casciano, C. N., Clement, R. P., & Johnson, W. W. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.1.160-165.2002 · Cited by 233
Oatp2 Mediates Bidirectional Organic Solute Transport: A Role for Intracellular Glutathione
Li, L., Meier, P. J., & Ballatori, N. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12069-x · Cited by 227
Olkkola, K. T., Ahonen, J., & Neuvonen, P. J. (1996) · Anesthesia & Analgesia · doi:10.1097/00000539-199603000-00015 · Cited by 224
Disposition of Posaconazole following Single-Dose Oral Administration in Healthy Subjects
Krieter, P., Flannery, B., Musick, T., Gohdes, M., Martinho, M., & Courtney, R. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.9.3543-3551.2004 · Cited by 212
Barone, J. A., Moskovitz, B. L., Guarnieri, J., Hassell, A. E., Colaizzi, J. L., Bierman, R. H., & Jessen, L. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.7.1862 · Cited by 208
Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study
Wexler, D., Courtney, R., Richards, W., Banfield, C., Lim, J., & Laughlin, M. (2004) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2004.01.005 · Cited by 199
Cyclophosphamide metabolism is affected by azole antifungals
Marr, K. A., Leisenring, W., Crippa, F., Slattery, J. T., Corey, L., Boeckh, M., & McDonald, G. B. (2004) · Blood · doi:10.1182/blood-2003-07-2512 · Cited by 190
Tucker, R. M., Denning, D. W., Hanson, L. H., Rinaldi, M. G., Graybill, J. R., Sharkey, P. K., Pappagianis, D., & Stevens, D. A. (1992) · Clinical Infectious Diseases · doi:10.1093/clinids/14.1.165 · Cited by 183
Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients
Trifilio, S., Ortiz, R., Pennick, G., Verma, A., Pi, J., Stosor, V, Zembower, T., & Mehta, J. (2005) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704828 · Cited by 180
Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies.
Black, D. J., Kunze, K. L., Wienkers, L. C., Gidal, B. E., Seaton, T. L., McDonnell, N. D., Evans, J. S., Bauwens, J. E., & Trager, W. F. (1996) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)07369-6 · Cited by 178
Itraconazole Decreases Renal Clearance of Digoxin
Jalava, K.-M., Partanen, J., & Neuvonen, P. J. (1997) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199712000-00001 · Cited by 176
Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin
Kivistö, K. T., Kantola, T., & Neuvonen, P. J. (1998) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1998.00034.x · Cited by 171
Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients
Romero, A. J., Pogamp, P. L., Nilsson, L., & Wood, N. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.121911 · Cited by 169
Increased Gastric pH and the Bioavailability of Fluconazole and Ketoconazole
Blum, R. A., D'Andrea, D. T., Florentino, B. M., Wilton, J. H., Hilligoss, D. M., Gardner, M. J., Henry, E. B., Goldstein, H., & Schentag, J. J. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-755 · Cited by 167
Effect of food on the pharmacokinetics of multiple‐dose oral voriconazole
Purkins, L., Wood, N., Kleinermans, D., Greenhalgh, K., & Nichols, D. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01994.x · Cited by 163
Pharmacokinetics of voriconazole and cytochrome p450 2C19 genetic status
IKEDA, Y. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.02.002 · Cited by 162
Aspergillus Meningitis: Diagnosis by Non-Culture-Based Microbiological Methods and Management
Verweij, P. E., Brinkman, K., Kremer, H. P. H., Kullberg, B.-J., & Meis, J. F. G. M. (1999) · Journal of Clinical Microbiology · doi:10.1128/jcm.37.4.1186-1189.1999 · Cited by 159
Self-citationMikus, G., SCHOWEL, V., Drzewinska, M., Rengelshausen, J., DING, R., RIEDEL, K., Burhenne, J., WEISS, J., Thomsen, T., & Haefeli, W. E. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.04.004 · Cited by 157
Pharmacokinetic Drug Interactions of Gefitinib with Rifampicin, Itraconazole and Metoprolol
Swaisland, H., Ranson, M., Smith, R. P., Leadbetter, J., Laight, A., McKillop, D., & Wild, M. J. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544100-00005 · Cited by 154
Pharmacokinetics of Posaconazole Coadministered with Antacid in Fasting or Nonfasting Healthy Men
Courtney, R., Radwanski, E., Lim, J. M., & Laughlin, M. A. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.3.804-808.2004 · Cited by 154
The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: A population study*
Balian, J. D., Sukhova, N., Harris, J. W., Hewett, J., Pickle, L. W., Goldstein, J. A., Woosley, R. L., & Flockhart, D. A. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90229-5 · Cited by 151
Voriconazole, a novel wide‐spectrum triazole: oral pharmacokinetics and safety
Purkins, L., Wood, N., Greenhalgh, K., Allen, M. J., & Oliver, S. D. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01993.x · Cited by 149
Itraconazole Therapy for Chronic Coccidioidal Meningitis
TUCKER, R. M., Denning, D. W., Dupont, B., & Stevens, D. A. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-112-2-108 · Cited by 148
Pharmacokinetics and Safety of Oral Posaconazole in Neutropenic Stem Cell Transplant Recipients
Gubbins, P. O., Krishna, G., Sansone‐Parsons, A., Penzak, S. R., Li, D., Martinho, M., & Anaissie, E. J. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00157-06 · Cited by 146
Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol
Lilja, J. J., Backman, J. T., Laitila, J., Luurila, H., & Neuvonen, P. J. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2003.26 · Cited by 142
Opposite effects of short-term and long-term St John’s wort intake on voriconazole pharmacokinetics
Rengelshausen, J., Banfield, M. J., RIEDEL, K., Burhenne, J., WEISS, J., Thomsen, T., Walter‐Sack, I., Haefeli, W. E., & Mikus, G. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.01.024 · Cited by 140
Saari, T. I., LAINE, K., Leino, K. A., Valtonen, M., Neuvonen, P. J., & Olkkola, K. T. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.12.305 · Cited by 137
Skov, M., Main, K. M., Ib, S., Müller, J., Koch, C., & Lanng, S. (2002) · European Respiratory Journal · doi:10.1183/09031936.02.00248002 · Cited by 136
Effect of omeprazole on the pharmacokinetics of itraconazole
Jaruratanasirikul, S., & Sriwiriyajan, S. (1998) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050438 · Cited by 135
The Triazole Antifungal Agents: A Review of Itraconazole and Fluconazole
Bailey, E. M., Krakovsky, D. J., & Rybak, M. J. (1990) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1990.tb02561.x · Cited by 129
Varis, T. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.110772 · Cited by 128
Itraconazole greatly increases plasma concentrations and effects of felodipine
Jalava, K.-M., Olkkola, K. T., & Neuvonen, P. J. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90191-0 · Cited by 127
Therapeutic Drug Monitoring of Voriconazole
Brüggemann, R. J. M., Donnelly, J. P., Aarnoutse, R. E., Warris, A., Blijlevens, N. M. A., Mouton, J. W., Verweij, P. E., & Burger, D. M. (2008) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e31817b1a95 · Cited by 126
Self-citationKovarik, J. M. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.118022 · Cited by 124
Effect of fluconazole on plasma fluvastatin and pravastatin concentrations
Kantola, T., Backman, J. T., Niemi, M., Kivistö, K. T., & Neuvonen, P. J. (2000) · European Journal of Clinical Pharmacology · doi:10.1007/s002280000127 · Cited by 122
Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration
Purkins, L., Wood, N., Ghahramani, P., Love, E. R., Eve, M. D., & Fielding, A. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01997.x · Cited by 120
Effect of fluconazole on the disposition of phenytoin
Blum, R. A., Wilton, J. H., Hilligoss, D. M., Gardner, M., Henry, E. B., Harrison, N. J., & Schentag, J. J. (1991) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1991.49 · Cited by 120
Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone
Jaakkola, T., Backman, J. T., Neuvonen, M., & Neuvonen, P. J. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.12.266 · Cited by 119
The pharmacokinetics and safety of intravenous voriconazole – a novel wide‐spectrum antifungal agent
Purkins, L., Wood, N., Greenhalgh, K., Eve, M. D., Oliver, S. D., & Nichols, D. J. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01992.x · Cited by 117
Effect of itraconazole on the pharmacokinetics of rosuvastatin
Cooper, K. D. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(02)17633-8 · Cited by 115
The effect of fluconazole on the pharmacokinetics of rosuvastatin
Cooper, K., Martin, P. D., Dane, A. L., Warwick, M. J., Schneck, D. W., & Cantarini, M. (2002) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-002-0508-8 · Cited by 113
Voriconazole and Sirolimus Coadministration after Allogeneic Hematopoietic Stem Cell Transplantation
Marty, F. M., Lowry, C. M., Cutler, C. S., Campbell, B., Fiumara, K., Baden, L. R., & Antin, J. H. (2006) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2005.12.032 · Cited by 112
Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174
KAUKONEN, K. ‐., Olkkola, K. T., & Neuvonen, P. J. (1998) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050405 · Cited by 111
Buggia, I., Zecca, M., Alessandrino, E. P., Locatelli, F., Rosti, G., Bosi, A., Pession, A., Rotoli, B., Majolino, I., Dallorso, A., et al. (1996) · PubMed · Cited by 109
Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL
Böhme, A., Ganser, A., & Hoelzer, D. T. (1995) · Annals of Hematology · doi:10.1007/bf01697985 · Cited by 108
Effect of omeprazole on the steady‐state pharmacokinetics of voriconazole
Wood, N., Tan, K., Purkins, L., Layton, G. R., Hamlin, J., Kleinermans, D., & Nichols, D. J. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.02000.x · Cited by 104
Honig, P. K., Wortham, D. C., Hull, R. W., Zamani, K., Smith, J. E., & Cantilena, L. R. (1993) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1993.tb03920.x · Cited by 104
Sansone‐Parsons, A., Krishna, G., Calzetta, A., Wexler, D. B., Kantesaria, B. S., Rosenberg, M. A., & Saltzman, M. A. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.5.1881-1883.2006 · Cited by 104
INTERACTION BETWEEN CYCLOSPORINE AND FLUCONAZOLE IN RENAL ALLOGRAFT RECIPIENTS
Canafax, D. M., Graves, N. M., Hilligoss, D. M., Carleton, B., Gardner, M., & Matas, A. J. (1991) · Transplantation · doi:10.1097/00007890-199105000-00016 · Cited by 103
Ahonen, J., Olkkola, K. T., & Neuvonen, P. J. (1995) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1995.tb00001.x · Cited by 96
FLUCONAZOLE THERAPY IN TRANSPLANT RECIPIENTS RECEIVING FK506
Máñez, R., Martin, M., Raman, D., et al. (1994) · Transplantation · doi:10.1097/00007890-199405270-00022 · Cited by 96
Osowski, C. L., Dix, S. P., Lin, L. S., Mullins, R. E., Geller, R. B., & Wingard, J. R. (1996) · Transplantation · doi:10.1097/00007890-199604270-00026 · Cited by 95
Lopinavir/ritonavir reduces lamotrigine plasma concentrations in healthy subjects
VANDERLEE, M., Dawood, L. H., TERHOFSTEDE, H., et al. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.04.014 · Cited by 94
Niemi, M., Tornio, A., Pasanen, M. K., Fredrikson, H., Neuvonen, P. J., & Backman, J. T. (2006) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-006-0133-z · Cited by 90
Itraconazole increases plasma concentrations of quinidine*
Kaukonen, K., Olkkola, K. T., & Neuvonen, P. J. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90046-1 · Cited by 90
Barone, J. A., Moskovitz, B. L., Guarnieri, J. A., Hassell, A. E., Colaizzi, J. L., Bierman, R. H., & Jessen, L. M. (1998) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1998.tb03856.x · Cited by 89
Interactions of azole antifungal agents with the human breast cancer resistance protein (BCRP)
Gupta, A., Unadkat, J. D., & Mao, Q. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20963 · Cited by 87
Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers*
Kazierad, D. J., Martin, D. E., Blum, R. A., et al. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90120-x · Cited by 87
Krishna, G., Parsons, A. C., Kantesaria, B. S., et al. (2007) · Current Medical Research and Opinion · doi:10.1185/030079906x167507 · Cited by 85
Ahonen, J., Olkkola, K. T., & Neuvonen, P. J. (1997) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050223 · Cited by 85
Voriconazole potentiates warfarin‐induced prothrombin time prolongation
Purkins, L., Wood, N., Kleinermans, D., & Nichols, D. J. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01995.x · Cited by 84
Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl
Saari, T. I., Laine, K., Neuvonen, M., et al. (2007) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-007-0398-x · Cited by 84
Kubo, M., Koue, T., Inaba, A., Takeda, H., Maune, H., Fukuda, T., & Azuma, J. (2005) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.20.55 · Cited by 84
Honig, P. K., Wortham, D. C., Zamani, K., Mullin, J. C., Conner, D. P., & Cantilena, L. R. (1993) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1993.83 · Cited by 83
Itraconazole-Related Increased Vincristine Neurotoxicity: Case Report and Review of Literature
Bermúdez, M., Fuster, J. L., Llinares, E., Galera, A., & Gonzalez, C. (2005) · Journal of Pediatric Hematology/Oncology · doi:10.1097/01.mph.0000172751.06286.5b · Cited by 82
Damkier, P., Hansen, L. L., & Brøsen, K. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00099.x · Cited by 79
Klont, R. R., Eggink, C. A., Rijs, A. J. M. M., Wesseling, P., & Verweij, P. E. (2005) · Clinical Infectious Diseases · doi:10.1086/430062 · Cited by 79
Self-citationDucharme, M. P., Slaughter, R. L., Warbasse, L. H., Chandrasekar, P. H., de Velde, V. V., Mannens, G., & Edwards, D. J. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90017-9 · Cited by 78
Liu, P., Foster, G., Gandelman, K., LaBadie, R. R., Allison, M. J., Gutierrez, M. J., & Sharma, A. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00526-07 · Cited by 78
The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone
Varis, T., Kivistö, K. T., & Neuvonen, P. J. (2000) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050720 · Cited by 75
Effect of fluconazole dose on the extent of fluconazole-triazolam interaction
Varhe, A., Olkkola, K. T., & Neuvonen, P. J. (1996) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1996.45111.x · Cited by 75
SHON, J., Yoon, Y. M., HONG, W., Nguyen, P. L., LEE, S., Choi, Y., Cha, I., & SHIN, J. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.04.012 · Cited by 73
Effect of rifampicin on the pharmacokinetics of itraconazole in normal volunteers and AIDS patients
Jaruratanasirikul, S., & Sriwiriyajan, S. (1998) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050437 · Cited by 72
Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride
Niemi, M., Backman, J. T., Neuvonen, M., Laitila, J., Neuvonen, P. J., & Kivistö, K. T. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.114229 · Cited by 71
Liu, P., Foster, G., LaBadie, R. R., Gutiérrez, M. J., & Sharma, A. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270007309703 · Cited by 71
Leather, H. L., Boyette, R., Tian, L., & Wingard, J. R. (2006) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2005.10.022 · Cited by 71
Severe vincristine toxicity in combination with itraconazole
Gillies, J., HUNG, K. A., Fitzsimons, E. J., et al. (1998) · Clinical & Laboratory Haematology · doi:10.1046/j.1365-2257.1998.00103.x · Cited by 69
Krishna, G., Moton, A., Ma, L., Savant, I. A., Martinho, M., Seiberling, M., & McLeod, J. F. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.02.022 · Cited by 68
Nulens, E., Eggink, C. A., Rijs, A. J. M. M., Wesseling, P., & Verweij, P. E. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.5.2261-2264.2003 · Cited by 68
Self-citationPotentiation of vincristine toxicity by itraconazole in children with lymphoid malignancies
Kamaluddin, M., McNally, P., Breatnach, F., Webb, D., O'Dell, E., Scanlon, P., Butler, K., O'Meara, A., & O'Marcaigh, A. (2001) · Acta Paediatrica · doi:10.1111/j.1651-2227.2001.tb03257.x · Cited by 67
ENHANCED VINCRISTINE NEUROTOXICITY FROM DRUG INTERACTIONS: Case Report and Review of Literature
Sathiapalan, R. K., & El‐Solh, H. (2001) · Pediatric Hematology and Oncology · doi:10.1080/088800101753328529 · Cited by 65
Varis, T., Kivistö, K. T., Backman, J. T., & Neuvonen, P. J. (1999) · Pharmacology & Toxicology · doi:10.1111/j.1600-0773.1999.tb01059.x · Cited by 62
Increased Plasma Rifabutin Levels with Concomitant Fluconazole Therapy in HIV-Infected Patients
Trapnell, C. B., Narang, P. K., Li, R., et al. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-124-6-199603150-00006 · Cited by 61
Effect of fluconazole dose on the extent of fluconazole‐triazolam interaction
Varhe, A., Olkkola, K. T., & Neuvonen, P. J. (1996) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1996.tb00009.x · Cited by 60
Fluconazole, but not terbinafine, enhances the effects of triazolam by inhibiting its metabolism
Varhe, A., Olkkola, K. T., & Neuvonen, P. J. (1996) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1996.03189.x · Cited by 59
Effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam
Yasui, N., Kondo, T., Otani, K., et al. (1998) · Psychopharmacology · doi:10.1007/s002130050715 · Cited by 59
JUNG, S., Kim, K., CHO, H., JUNG, I., Park, P., BYUN, W., & Park, J. Y. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.07.007 · Cited by 58
Krishna, G., Sansone‐Parsons, A., & Kantesaria, B. S. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x187937 · Cited by 58
Liu, P., Foster, G., LaBadie, R. R., Somoza, E. C., & Sharma, A. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00559-06 · Cited by 57
Shitrit, D., Ollech, J. E., Ollech, A., Bakal, I., Saute, M., Sahar, G., & Kramer, M. R. (2005) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2005.05.003 · Cited by 56
The CYP 3A4 inhibitor itraconazole has no effect on the pharmacokinetics of i.v. fentanyl
Palkama, V. J., Neuvonen, P. J., & Olkkola, K. T. (1998) · British Journal of Anaesthesia · doi:10.1093/bja/81.4.598 · Cited by 56
Therapeutic drug monitoring of itraconazole and the relevance of pharmacokinetic interactions
Hurlé, A. D.-G., Navarro, A. S., & Sánchez, M. J. G. (2006) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2006.01611.x · Cited by 55
Interaction between fluconazole and midazolam in intensive care patients
Ahonen, J., Olkkola, K. T., Takala, A., et al. (1999) · Acta Anaesthesiologica Scandinavica · doi:10.1034/j.1399-6576.1999.430504.x · Cited by 55
Effect of Rifampicin on the Pharmacokinetics of Fluconazole in Patients with AIDS
Ayudhya, D. P. N., Thanompuangseree, N., & Tansuphaswadikul, S. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443110-00003 · Cited by 55
The effect of ingestion time interval on the interaction between itraconazole and triazolam
Neuvonen, P. J., Varhe, A., & Olkkola, K. T. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90059-4 · Cited by 53
ITRACONAZOLE-ENHANCED VINCRISTINE NEUROTOXICITY IN A CHILD WITH ACUTE LYMPHOBLASTIC LEUKEMIA
Jeng, M., & Feusner, J. H. (2001) · Pediatric Hematology and Oncology · doi:10.1080/088800101300002973 · Cited by 53
Johnson, M. D., Hamilton, C. D., Drew, R. H., Sanders, L. L., Pennick, G. J., & Perfect, J. R. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg089 · Cited by 53
Florea, N. R., Capitano, B., Nightingale, C. H., Hull, D., Leitz, G. J., & Nicolau, D. P. (2003) · Transplantation Proceedings · doi:10.1016/j.transproceed.2003.10.058 · Cited by 52
Raaska, K., & Neuvonen, P. J. (1998) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050440 · Cited by 51
Grapefruit Juice Decreases the Systemic Availability of Itraconazole Capsules in Healthy Volunteers
Penzak, S. R., Gubbins, P. O., Gurley, B. J., et al. (1999) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199906000-00009 · Cited by 50
Sinofsky, F. E., & Pasquale, S. A. (1998) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(98)80016-1 · Cited by 50
Effect of erythromycin and itraconazole on the pharmacokinetics of intravenous lignocaine
Isohanni, M. H., Neuvonen, P. J., Palkama, V. J., et al. (1998) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050513 · Cited by 49
Buijk, S. L. C. E., Gyssens, I. C., Mouton, J. W., Verbrugh, H. A., Touw, D. J., & Bruining, H. A. (2001) · Intensive Care Medicine · doi:10.1007/s001340000771 · Cited by 45
Voriconazole does not affect the steady‐state pharmacokinetics of digoxin
Purkins, L., Wood, N., Kleinermans, D., & Nichols, D. J. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01998.x · Cited by 44
Voriconazole and fluconazole increase the exposure to oral diazepam
Saari, T. I., Laine, K., Bertilsson, L., Neuvonen, P. J., & Olkkola, K. T. (2007) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-007-0350-0 · Cited by 44
Andrews, E. N., Damle, B. D., Fang, A. F., Foster, G., Crownover, P. H., LaBadie, R. R., & Glue, P. (2008) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2007.03084.x · Cited by 43
Rifampin-Fluconazole Interaction in Critically ILL Patients
Nicolau, D. P., Crowe, H. M., Nightingale, C. H., et al. (1995) · Annals of Pharmacotherapy · doi:10.1177/106002809502901007 · Cited by 42
Purkins, L., Wood, N., Kleinermans, D., & Nichols, D. J. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01999.x · Cited by 42
Park, J. Y., Shon, J., Kim, K., Jung, H.-J., Shim, J.-C., Yoon, Y.-R., Cha, I., & Shin, J. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000203199.88581.c3 · Cited by 42
Evaluation of interaction between fluconazole and an oral contraceptive in healthy women
Hilbert, J. (2001) · Obstetrics and Gynecology · doi:10.1016/s0029-7844(01)01443-0 · Cited by 42
Palkama, V. J., Isohanni, M. H., Neuvonen, P. J., et al. (1998) · Anesthesia & Analgesia · doi:10.1213/00000539-199807000-00039 · Cited by 42
Steady State Parenteral Kinetics of Fluconazole in Man
Foulds, G. H., Wajszczuk, C. P., Weidler, D. J., Garg, D., & GIBSON, P. (1988) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1988.tb40440.x · Cited by 41
Araki, K., Yasui‐Furukori, N., Fukasawa, T., Aoshima, T., Suzuki, A., Inoue, Y., Tateishi, T., & Otani, K. (2004) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-004-0789-1 · Cited by 39
Vincristine toxicity in five children with acute lymphoblastic leukaemia
Murphy, J. A., Ross, L. M., & Gibson, B. E. S. (1995) · The Lancet · doi:10.1016/s0140-6736(95)92816-2 · Cited by 39
Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zolpidem
Luurila, H., Kivistö, K. T., & Neuvonen, P. J. (1998) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050439 · Cited by 39
Shimizu, M., Uno, T., Sugawara, K., & Tateishi, T. (2006) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2006.02689.x · Cited by 38
Wit, S. D., Debier, M., Smet, M. D., McCrea, J. B., Stone, J. A., Carides, A. D., Matthews, C., Deutsch, P., & Clumeck, N. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.2.223 · Cited by 38
Jordan, M. K., Polis, M. A., Kelly, G., et al. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.8.2170-2172.2000 · Cited by 37
Purkins, L., Wood, N., Ghahramani, P., Kleinermans, D., Layton, G. R., & Nichols, D. J. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01996.x · Cited by 35
Effect of Erythromycin and Itraconazole on the Pharmacokinetics of Oral Lignocaine
Isnhanni, M. H., Neuvonen, P. J., & Olkkola, K. T. (1999) · Pharmacology & Toxicology · doi:10.1111/j.1600-0773.1999.tb00890.x · Cited by 35
The influence of gastric pH on the pharmacokinetics of fluconazole: the effect of omeprazole.
Zimmermann, T., Yeates, R. A., Riedel, K. D., Lach, P., & Laufen, H. (1994) · PubMed · Cited by 34
Pharmacokinetic interactions of efavirenz and voriconazole in healthy volunteers
Damle, B. D., LaBadie, R. R., Crownover, P. H., & Glue, P. (2008) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2007.03085.x · Cited by 34
Lack of Dose-Dependent Effects of Itraconazole on the Pharmacokinetic Interaction with Fexofenadine
Uno, T., Shimizu, M., Sugawara, K., & Tateishi, T. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.011023 · Cited by 34
Renal Interaction Between Itraconazole and Cimetidine
Karyekar, C. S., Eddington, N. D., Briglia, A., Gubbins, P. O., & Dowling, T. C. (2004) · The Journal of Clinical Pharmacology · doi:10.1177/0091270004266783 · Cited by 33
SEVERE VINCRISTINE NEUROTOXICITY WITH CONCOMITANT USE OF ITRACONAZOLE
Ariffin, H., Omar, K., Ang, E. L., & Krishnan, S. (2003) · Journal of Paediatrics and Child Health · doi:10.1046/j.1440-1754.2003.00255.x · Cited by 32
The effect of the antimycotic itraconazole on the pharmacokinetics and pharmacodynamics of diazepam
Ahonen, J., Olkkola, K. T., & Neuvonen, P. J. (1996) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.1996.tb00312.x · Cited by 31
Purkins, L., Wood, N., Kleinermans, D., & Love, E. R. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.02001.x · Cited by 30
Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zopiclone
Jalava, K.-M., Olkkola, K. T., & Neuvonen, P. J. (1996) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050207 · Cited by 28
Pharmacokinetic study of the interaction between itraconazole and nevirapine
Jaruratanasirikul, S., & Sriwiriyajan, S. (2007) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-007-0280-x · Cited by 27
Evaluation of the effect of fluconazole on the pharmacokinetics of ritonavir.
Cato, A. E., Cao, G., Hsu, A., et al. (1997) · PubMed · Cited by 27
Effect of Clarithromycin and Itraconazole on the Pharmacokinetics of Ropivacaine
Jokinen, M. J., Ahonen, J., Neuvonen, P. J., & Olkkola, K. T. (2001) · Pharmacology & Toxicology · doi:10.1034/j.1600-0773.2001.d01-102.x · Cited by 26
Clinical Pharmacology of Fluconazole
Dudley, M. N. (1990) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1990.tb02599.x · Cited by 26
Pharmacokinetic interaction of fluconazole and zidovudine in HIV-positive patients.
Brockmeyer, N. H., Tillmann, I., Mertins, L., et al. (1997) · PubMed · Cited by 25
Clinical Pharmacokinetic Monitoring of Itraconazole Is Warranted in Only a Subset of Patients
Buchkowsky, S. S., Partovi, N., & Ensom, M. H. H. (2005) · Therapeutic Drug Monitoring · doi:10.1097/01.ftd.0000150135.22645.ea · Cited by 25
Effect of Terbinafine and Voriconazole on the Pharmacokinetics of the Antidepressant Venlafaxine
Hynninen, V.-V., Olkkola, K. T., Bertilsson, L., et al. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100311 · Cited by 25
Winter, H. R., TRAPNELL, C., Slattery, J. T., JACOBSON, M., GREENSPAN, D., HOOTON, T., & Unadkat, J. D. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.08.016 · Cited by 24
Borin, M. T., Cox, S. R., Herman, B. D., Carel, B. J., Anderson, R. D., & Freimuth, W. W. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.9.1892 · Cited by 23
Effect of voriconazole on the pharmacokinetics and pharmacodynamics of zolpidem in healthy subjects
Saari, T. I., Laine, K., Leino, K. A., Valtonen, M., Neuvonen, P. J., & Olkkola, K. T. (2006) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2006.02707.x · Cited by 23
Furukori, H., Kondo, T., Yasui, N., Otani, K., Tokinaga, N., Nagashima, U., Kaneko, S., & Inoue, Y. (1999) · Psychopharmacology · doi:10.1007/s002130051048 · Cited by 23
Vincristine–Itraconazole Interaction: Cause for Increasing Concern
Sathiapalan, R. K., Al-Nasser, A., El‐Solh, H., Al-Mohsen, I. Z., & Aljumaah, S. (2002) · Journal of Pediatric Hematology/Oncology · doi:10.1097/00043426-200210000-00023 · Cited by 23
Potential Interaction between Itraconazole and Clarithromycin
Auclair, B., Berning, S. E., Huitt, G. A., et al. (1999) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.19.18.1439.30907 · Cited by 22
Lukkari, E., Juhakoski, A., Aranko, K., & Neuvonen, P. J. (1997) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050309 · Cited by 21
No Effect of Itraconazole on the Single Oral Dose Pharmacokinetics and Pharmacodynamics of Estazolam
Otsuji, Y., Okuyama, N., Aoshima, T., Fukasawa, T., Kato, K., Gerstenberg, G., Miura, M., Ohkubo, T., Sugawara, K., & Otani, K. (2002) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200206000-00008 · Cited by 20
Lack of Effect of Antimycotic Itraconazole on the Pharmacokinetics or Pharmacodynamics of Temazepam
Ahonen, J., Olkkola, K. T., & Neuvonen, P. J. (1996) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199604000-00003 · Cited by 20
A Fluconazole/Amitriptyline Drug Interaction in Three Male Adults
Newberry, D. L., Bass, S. N., Mbanefo, C. O., et al. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.2.270 · Cited by 18
Naef, R., Schmid, C., Höfer, M., Minder, S. P., Speich, R., & Boehler, A. (2006) · Respiration · doi:10.1159/000095941 · Cited by 18
Scott, G., Yih, L., Yeh, C., et al. (2004) · The Journal of Clinical Pharmacology · doi:10.1177/0091270003262110 · Cited by 15
Bruzzese, V. L., Gillum, J. G., Israel, D. S., et al. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.5.1050 · Cited by 15
Vanakoski, J., Mattila, M. J., Vainío, P. J., Idänpään-Heikkilä, J. J., & Törnwall, M. E. (1995) · PubMed · Cited by 14
Lack of effect of fluconazole on the pharmacokinetics of rifampicin in AIDS patients
Jaruratanasirikul, S., & Kleepkaew, A. (1996) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/38.5.877 · Cited by 12
Effect of Itraconazole on the Pharmacokinetics of Atenolol
Lilja, J. J., Backman, J. T., & Neuvonen, P. J. (2005) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2005.pto_223.x · Cited by 11
Cabergoline plasma concentration is increased during concomitant treatment with itraconazole
Christensen, J., Dupont, E., & Østergaard, K. (2002) · Movement Disorders · doi:10.1002/mds.10250 · Cited by 10
Lack of a kinetic interaction between fluconazole and mexiletine
Ueno, K., Yamaguchi, R., Tanaka, K., et al. (1996) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050080 · Cited by 8
Ritonavir-dependent fluconazole boosting of nelfinavir: a report of three cases
Garazzino, S. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl232 · Cited by 3
Cited by
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ933 · Cited by 4,200
Patterson, T. F., Thompson, G. R., Denning, D. W., Fishman, J. A., Hadley, S., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Nguyen, M. H., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw326 · Cited by 2,926
Sexually Transmitted Infections Treatment Guidelines, 2021
Workowski, K. A., Bachmann, L. H., Chan, P. A., Johnston, C. M., Muzny, C. A., Park, I., Reno, H., Zenilman, J. M., & Bolan, G. A. (2021) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr7004a1 · Cited by 3,018
Sexually Transmitted Diseases Treatment Guidelines, 2010
(2011) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2011.04.006 · Cited by 2,076
Ashbee, H. R., Barnes, R. A., Johnson, E. M., Richardson, M. D., Gorton, R., & Hope, W. W. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt508 · Cited by 716
Metadata
- Authors
- Brüggemann, R. J. M., Alffenaar, J. C., Blijlevens, N. M. A., Billaud, E. M., Kosterink, J. G. W., Verweij, P. E., & Burger, D. M.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-05-15
- Volume
- 48
- Issue
- 10
- Pages
- 1441-1458
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2121237805
- Cited by
- 457
- References
- 179
- FWCI
- 15.71
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.